Investigating the role of MLL1 in cancer development
Official title: Non-canonical function of transcription cofactor MLL1 in cancer
Funded at University of Southern California · NIH-11015831 · Data updated 2026-11-12
This study is looking at how a protein called MLL1, which can change in different cancers, affects the growth of liver cancer, with the hope of finding new ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $510,646 |
| NIH project number | 5R01CA287625-02 |
| Project ID | NIH-11015831 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute lymphoblastic leukemia or other cancers linked to MLL1 abnormalities.
✕Less likely to help
Patients with cancers unrelated to MLL1 mutations may not benefit from this research.
What this research studies
This research explores how the MLL1 protein, which is often altered in various cancers, influences cancer growth and progression. By examining both its traditional role in gene transcription and its other functions, the study aims to uncover new mechanisms that contribute to cancer development. The research employs a variety of scientific techniques to analyze MLL1's impact on cellular processes, particularly in liver cancer. The findings could lead to new therapeutic strategies targeting MLL1.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for cancers associated with MLL1 mutations, improving patient outcomes.
How similar studies have gone: Previous research has shown promising results in targeting chromatin modifying enzymes in cancer therapy, suggesting potential for success in this approach.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Dou, Yali — University of Southern California
- Study coordinator: Dou, Yali
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.